ProQR Therapeutics
PRQR
65 hedge funds and large institutions have $54.9M invested in ProQR Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 19 closing their positions.
100% more call options, than puts
Call options by funds: $66K | Put options by funds: $33K
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
3.8% less ownership
Funds ownership: 43.05% → 39.25% (-3.8%)
16% less funds holding
Funds holding: 77 → 65 (-12)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less capital invested
Capital invested by funds: $118M → $54.9M (-$62.8M)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$3.94M |
| 2 |
Morgan Stanley
New York
|
+$1.91M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$978K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$873K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$373K |
Top Sellers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$4.75M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.19M |
| 3 |
Millennium Management
New York
|
-$1.61M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.58M |
| 5 |
ACM
Altium Capital Management
New York
|
-$1.52M |
PRQR Hedge Fund Activity: Q1 2025 in Review
65 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2025, worth a combined $54.9M — down 53% from $118M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PRQR and 7 opened new positions — a net loss of 12 holders — while 19 trimmed existing stakes and 18 added.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $3.94M. The largest seller was Woodline Partners, cutting an estimated $4.75M.
- 65 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2025, down from 77 in Q4 2024.
- Funds reported $54.9M of ProQR Therapeutics stock for Q1 2025, down 53% quarter-over-quarter.
- 7 funds opened new ProQR Therapeutics positions in Q1 2025 and 19 closed out, a net change of -12 holders.
- The largest ProQR Therapeutics buyer in Q1 2025 was Aberdeen Group, an estimated $3.94M added.
- The largest ProQR Therapeutics seller in Q1 2025 was Woodline Partners, an estimated $4.75M sold.
Based on aggregated 13F filings for Q1 2025.